Methylglyoxal in diabetes: Link to treatment, glycaemic control and biomarkers of complications

Biochemical Society Transactions

Volumn 42, Issue 2, 2014, Pages 450-456

  Beisswenger, Paul J ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Advanced glycation end product (AGE); Diabetic complication; Glycaemic fluctuation; Mass spectrometry; Metformin; Methylglyoxal

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; BIOLOGICAL MARKER; GLUCOSE; GLYOXAL; GLYOXALASE; HEMOGLOBIN A1C; METFORMIN; METHYLGLYOXAL;

BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; ANIMAL; DIABETES COMPLICATIONS; MASS SPECTROMETRY; METABOLISM;

ANIMALS; DIABETES COMPLICATIONS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MASS SPECTROMETRY; METFORMIN; PYRUVALDEHYDE;

EID: 84896979660     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20130275     Document Type: Review

References (59)

1. Saaddine, J.B., Honeycutt, A.A., Narayan, K.M., Zhang, X., Klein, R. and Boyle, J.P. (2008) Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch. Ophthalmol. 126, 1740-1747
2. Nathan, D.M., Davidson, M.B., DeFronzo, R.A., Heine, R.J., Henry, R.R., Pratley, R. and Zinman, B. (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30, 753-759 (Pubitemid 46354366)
3. Hunt, K.J., Williams, K., Hazuda, H.P., Stern, M.P. and Haffner, S.M. (2007) The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. Ann. Epidemiol. 17, 870-877 (Pubitemid 47588953)
4. Yang, W., Dall, T.M., Halder, P., Gallo, P., Kowal, S.L. and Hogan, P.F. (2013) Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36, 1033-1046
5. The Diabetes Control and Complications Trial Research Group (1997) Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 46, 1829-1839
6. Fioretto, P., Steffes, M.W., Barbosa, J., Rich, S.S., Miller, M.E. and Mauer, M. (1999) Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes 48, 865-869 (Pubitemid 29153088)
7. Seaquist, E.R., Goetz, F.C., Rich, S. and Barbosa, J. (1989) Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N. Engl. J. Med. 320, 1161-1165 (Pubitemid 19124296)
8. Andersen, A.R., Christiansen, J.S., Andersen, J.K., Kreiner, S. and Deckert, T. (1983) Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25, 496-501 (Pubitemid 14200886)
9. Krolewski, A.J., Warram, J.H., Kahn, R., Kahn, L.I. and Kahn, C.R. (1987) Epidemiologic approach to the etiology of Type I diabetes mellitus and its complications. N. Engl. J. Med. 18, 267-273
10. 1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44, 968-983
11. Haffner, S.M. (1998) The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr. Rev. 19, 583-592
12. Turner, R.C., Millns, H., Neil, H.A., Stratton, I.M., Manley, S.E., Matthews, D.R. and Holman, R.R. (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316, 823-828 (Pubitemid 28112428)
13. Ong, K.L., Cheung, B.M., Wong, L.Y., Wat, N.M., Tan, K.C. and Lam, K.S. (2008) Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann. Epidemiol. 18, 222-229
14. Amin, R., Widmer, B., Dalton, R.N. and Dunger, D.B. (2009) Unchanged incidence of microalbuminuria in children with type 1 diabetes since 1986: a UK based inception cohort. Arch. Dis. Child. 94, 258-262
15. Prince, C.T., Becker, D.J., Costacou, T., Miller, R.G. and Orchard, T.J. (2007) Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50, 2280-2288 (Pubitemid 47512402)
16. Niwa, T. (2008) Biomarker discovery for kidney diseases by mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 870, 148-153
17. Monnier, V.M., Sell, D.R., Dai, Z., Nemet, I., Collard, F. and Zhang, J. (2008) The role of the Amadori product in the complications of diabetes. Ann. N.Y. Acad. Sci. 1126, 81-88 (Pubitemid 351589314)
18. Monnier, V.M., Sell, D.R. and Genuth, S. (2005) Glycation products as markers and predictors of the progression of diabetic complications. Ann. N.Y. Acad. Sci. 1043, 567-581 (Pubitemid 41123947)
19. Baynes, J.W. and Thorpe, S.R. (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28, 1708-1716 (Pubitemid 30628657)
20. Yu, Y., Thorpe, S.R., Jenkins, A.J., Shaw, J.N., Sochaski, M.A., McGee, D., Aston, C.E., Orchard, T.J., Silvers, N., Peng, Y.G. et al. (2006) Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia 49, 2488-2498 (Pubitemid 44359112)
21. Kilhovd, B.K., Giardino, I., Torjesen, P.A., Birkeland, K.I., Berg, T.J., Thornalley, P.J., Brownlee, M. and Hanssen, K.F. (2003) Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52, 163-167 (Pubitemid 36388837)
22. Nagai, R., Johno, T., Miyazaki, K. and Horiuchi, S. (2000) Preparation of specific antibodies against CML, one of the major AGE structures. Diabetes 49 (Suppl. 1), A144
23. em, reflect advanced glycation and oxidation end products in human skin without diabetes. Diabetes Technol. Ther. 14, 1-8
24. Lutgers, H.L., Graaff, R., Links, T.P., Ubink-Veltmaat, L.J., Bilo, H.J., Gans, R.O. and Smit, A.J. (2006) Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 29, 2654-2659 (Pubitemid 44912194)
25. 1c, vascular and tissue markers. Transl. Res. 159, 303-312
26. Thornalley, P.J., Battah, S., Ahmed, N., Karachalias, N., Agalou, S., Babaei-Jadidi, R. and Dawnay, A. (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375, 581-592 (Pubitemid 37433506)
27. Baynes, J. and Thorpe, S. (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48, 1-9 (Pubitemid 29019345)
28. Beisswenger, P., Drummond, K., Nelson, R., Howell, S., Szwergold, B. and Mauer, M. (2005) Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 54, 3274-3281 (Pubitemid 43334385)
29. Brownlee, M. (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615-1625
30. Ahmed, N., Babaei-Jadidi, R., Howell, S., Beisswenger, P. and Thornalley, P. (2005) Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48, 1590-1603 (Pubitemid 41175513)
31. Ahmed, N., Babaei-Jadidi, R., Howell, S., Thornalley, P. and Beisswenger, P. (2005) Glycated and oxidised protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 28, 2465-2471 (Pubitemid 41384295)
32. Beisswenger, P.J., Howell, S., Mauer, M., Russell, G., Miller, M. and Rich, S. (2013) Early progression of diabetic nephropathy correlates with methylglyoxal derived advanced glycation end products (AGEs). Diabetes Care 36, 3234-3239
33. Weil, E.J., Fufaa, G., Jones, L.I., Lovato, T., Lemley, K.V., Hanson, R.L., Knowler, W.C., Bennett, P.H., Yee, B., Myers, B.D. and Nelson, R.G. (2013) Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with Type 2 diabetes. Diabetes 62, 3224-3231
34. Chiasson, J.L., Josse, R.G., Gomis, R., Hanefeld, M., Karasik, A. and Laakso, M. (2002) Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359, 2072-2077 (Pubitemid 34680970)
35. The DECODE study group on behalf of the Europe and Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354, 617-621
36. Del Prato, S. (2002) In search of normoglycaemia in diabetes: controlling postprandial glucose. Int. J. Obes. Relat. Metab. Disord. 26 (Suppl. 3), S9-S17
37. Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H.J. and Lindner, J. (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39, 1577-1583 (Pubitemid 26397370)
38. Muggeo, M., Verlato, G., Bonora, E., Zoppini, G., Corbellini, M. and de Marco, R. (1997) Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 96, 1750-1754 (Pubitemid 27400729)
39. Shichiri, M., Kishikawa, H., Ohkubo, Y. and Wake, N. (2000) Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 (Suppl. 2), B21-B29 (Pubitemid 30185774)
40. Chiasson, J.L., Josse, R.G., Gomis, R., Hanefeld, M., Karasik, A. and Laakso, M. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290, 486-494 (Pubitemid 37430502)
41. Thornalley, P.J. (1996) Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification: a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 27, 565-573
42. Beisswenger, P., Howell, S., O'Dell, R., Wood, M., Touchette, A. and Szwergold, B. (2001) α-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24, 726-732 (Pubitemid 32888855)
43. Beisswenger, P., Tamber, M., LaPoint, N., Keshavarz, T., Howell, S. and Baron, M. (2004) Nateglinide reduces post-prandial glucose and methylglyoxal levels in Type 2 diabetes. Diabetes 53 (Suppl. 2), A471
44. Ceriello, A. (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54, 1-7
45. Ceriello, A., Quagliaro, L., Catone, B., Pascon, R., Piazzola, M., Bais, B., Marra, G., Tonutti, L., Taboga, C. and Motz, E. (2002) Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25, 1439-1443 (Pubitemid 41071158)
46. Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.P. and Colette, C. (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. JAMA 295, 1681-1687
47. Beisswenger, P., Howell, S., Touchette, A., Lal, S. and Szwergold, B. (1999) Metformin reduces systemic methylglyoxal levels in Type 2 diabetes. Diabetes 48, 198-202 (Pubitemid 29019373)
48. Beisswenger, P. and Ruggiero-Lopez, D. (2003) Metformin inhibition of glycation processes. Diabetes Metab. 29, 6S95-6S103
49. Brownlee, M. (1992) Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15, 1835-1843
50. Hammes, H., Martin, S., Federlin, K., Geisen, K. and Brownlee, M. (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. U.S.A. 88, 11555-11558 (Pubitemid 21916080)
51. Zimmerman, G., Meistrell, M., Bloom, O., Cockroft, K., Bianchi, M., Risucci, D., Broome, J., Farmer, P., Cerami, A. and Vlassara, H. (1995) Neurotoxicity of advanced glycosylation end products during focal stroke and neuroprotective effects of aminoguanidine. Proc. Natl. Acad. Sci. U.S.A. 92, 3744-3748
52. Appel, G., Bolton, K., Freedman, B., Wuerth, J.P. and Cartwright, K. (1999) Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of overt diabetic nephropathy in patients with Type I diabetes mellitus (DM). J. Am. Soc. Nephrol. 10, 153 A
53. Raskin, P., Cattran, D., Williams, M., Wuerth, J.-P. and Cartwright, K. (1999) Pimagedine (PG) reduces progression of retinopathy and lowers lipid levels in patients with Type I diabetes mellitus. J. Am. Soc. Nephrol. 10, 179 A
54. Bailey, C.J. (1992) Biguanides and NIDDM. Diabetes Care 15, 755-772
55. Wiernsperger, N.F. (2000) Metformin: intrinsic vasculoprotective properties. Diabetes Technol. Ther. 2, 259-272
56. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865
57. Ruggiero-Lopez, D., Lecomte, M., Moinet, G., Patereau, G., Lagarde, M. and Wiernsperger, N. (1999) Reaction of metformin with dicarbonyl compounds: possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 58, 1765-1773 (Pubitemid 29505417)
58. Tanaka, Y., Uchino, H., Shimizu, T., Yoshii, H., Niwa, M., Ohmura, C., Mitsuhashi, N., Onuma, T. and Kawamori, R. (1999) Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 376, 17-22 (Pubitemid 29320165)
59. Rabbani, N., Chittari, M.V., Bodmer, C.W., Zehnder, D., Ceriello, A. and Thornalley, P.J. (2010) Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 59, 1038-1045